| Literature DB >> 21393005 |
T Yamamoto1, K Nakai, T Nariai, H Kumada, T Okumura, M Mizumoto, K Tsuboi, A Zaboronok, E Ishikawa, H Aiyama, K Endo, T Takada, F Yoshida, Y Shibata, A Matsumura.
Abstract
The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m(2)) for the treatment of newly diagnosed GBM. BPA uptake is determined by (18)F-BPA-PET and/or (11)C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival. Copyright ÂEntities:
Mesh：
Substances：
Year: 2011 PMID： 21393005 DOI： 10.1016/j.apradiso.2011.02.013
Source DB: PubMed Journal: Appl Radiat Isot ISSN： 0969-8043 Impact factor: 1.513